CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Eichler, Tilo W ^a   Totland, Cecilie ^a   Haugen, Mette ^b   Qvale, Tor H ^a   Mazengia, Kibret ^a   Storstein, Anette ^b   Haukanes, Bjørn I ^b   Vedeler, Christian A ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CDR2 ANTIBODY; CDR2L ANTIBODY; GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN; CDR2L ANTIGEN, HUMAN; NERVE PROTEIN;

ANTIBODY SCREENING; ARTICLE; BLOOD DONOR; BREAST CANCER; CELL MEMBRANE; CONFOCAL MICROSCOPY; CYTOPLASM; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PARANEOPLASTIC NEUROPATHY; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; BREAST TUMOR; CASE CONTROL STUDY; COMPLICATION; FEMALE; GENETICS; HELA CELL LINE; IMMUNOLOGY; OVARY TUMOR; PURKINJE CELL; WESTERN BLOTTING;

AUTOANTIBODIES; AUTOANTIGENS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; NERVE TISSUE PROTEINS; OVARIAN NEOPLASMS; PARANEOPLASTIC CEREBELLAR DEGENERATION; PURKINJE CELLS;

EID: 84879138660     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066002     Document Type: Article

References (16)

1. Darnell RB, Posner JB, (2003) Paraneoplastic Syndromes Involving the Nervous System. New England Journal of Medicine 349: 1543-1554.
2. Storstein A, Monstad SE, Haugen M, Mazengia K, Veltman D, et al. (2011) Onconeural antibodies: Improved detection and clinical correlations. Journal of Neuroimmunology 232: 166-170.
3. Storstein A, Krossnes BK, Vedeler CA, (2009) Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurologica Scandinavica 120: 64-67.
4. Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, et al. (2010) Purkinje Cell Death After Uptake of Anti-Yo Antibodies in Cerebellar Slice Cultures. Journal of Neuropathology & Experimental Neurology 69: 997-1007 1010.1097/NEN.1000b1013e3181f1000c1082b.
5. O'Donovan KJ, Diedler J, Couture GC, Fak JJ, Darnell RB, (2010) The Onconeural Antigen cdr2 Is a Novel APC/C Target that Acts in Mitosis to Regulate C-Myc Target Genes in Mammalian Tumor Cells. PLoS ONE 5: e10045.
6. Monstad SE, Knudsen A, Salvesen H, Aarseth J, Vedeler C, (2009) Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunology, Immunotherapy 58: 1795-1800.
7. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, et al. (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. Journal of Neurology, Neurosurgery & Psychiatry 75: 1135-1140.
8. Monstad SE, Storstein A, Dørum A, Knudsen A, Lønning PE, et al. (2006) Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clinical & Experimental Immunology 144: 53-58.
9. Totland C, Aarseth J, Vedeler C, (2007) Hu and Yo antibodies have heterogeneous avidity. Journal of Neuroimmunology 185: 162-167.
10. Bittins C, Eichler T, Hammer J III, Gerdes H-H, (2010) Dominant-Negative Myosin Va Impairs Retrograde but Not Anterograde Axonal Transport of Large Dense Core Vesicles. Cellular and Molecular Neurobiology 30: 369-379.
11. Totland C, Aarskog N, Eichler T, Haugen M, Nøstbakken J, et al. (2011) CDR2 antigen and Yo antibodies. Cancer Immunology, Immunotherapy 60: 283-289.
12. Rossi CL, (1998) A Simple, Rapid Enzyme-linked Immunosorbent Assay for Evaluating Immunoglobulin G Antibody Avidity in Toxoplasmosis. Diagnostic Microbiology and Infectious Disease 30: 25-30.
13. Vincent A, (2008) Autoimmune disorders of the neuromuscular junction. Neurol India 56(3): 305-313.
14. Vincent A, Irani SR, Lang B (2010) The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Current Opinion in Neurology 23: 144-150 110.1097/WCO.1090b1013e32833735fe.
15. Hida C TTAHYT, (1994) ULtrastructural localization of anti-purkinje cell antibody-binding sites in paraneoplastic cerebellar degeneration. Archives of Neurology 51: 555-558.
16. Albert ML DJ, Bender A, Francisco LM, Bhardwaj N, Darnell RB, (1998) Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nature Medicine 4: 1321-1324.